AltheaDx Adds Next-Gen Sequencing Services for Biomarker Discovery, Clinical Trial Testing | GenomeWeb

AltheaDx has added next-generation sequencing services to its clinical molecular pathology laboratory for applications in cancer biomarker discovery and clinical trial testing, the company said this week.

AltheaDx CEO Francois Ferre said in a statement that next-gen sequencing will be "highly synergistic" with the company's strategy of creating cancer-specific molecular subtype panels in partnership with Compendia Bioscience. In addition, the technology will be "highly complementary" to AltheaDx's RT-PCR-based gene expression panels.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.